Q: When will IMMray™ PanCan-d be available to order?

A: IMMray™ PanCand test is in its late development phase, and it is planned to make the test available after the clinical evidence studies will be finalized. We will update the website as soon as we have the results of the studies.


Q: How early can the test detect pancreatic cancer?

A: Current state-of-the-art technologies generally detect pancreatic cancer in stage III or IV when it is normally not resectable. IMMray™ PanCan-d can detect cancer in stage I or II. Consequently, significantly more patients can undergo surgery and the survival rate could increase from 4% to approximately 60%.


Q: Why did you choose these biomarker signatures?

A: Since the immune system is trained to respond specifically and early towards any disease, exploring the immune system as a specific, sensitive and early sensor for disease is very appealing. We first screen a large set of potential biomarkers and then condense the list into a short (5 to 25 markers) defined panel providing the best specificity and sensitivity.


Q: How much sample do you need for testing?

A: IMMray™ PanCan-d works with as little as one drop of blood, which is less than 1 µl. For optimal sample handling, however, we prefer 20 µl.


Q: How do you know it is cancer and not another inflammatory condition?

A: On the basis of >900 patient sample studies, Immunovia’ 25-protein signature discriminates pancreatic cancer vs. pancreatitis and healthy individuals with high specificity / sensitivity (>95%)



Q: How much does it cost and how can I order a test?

A: The test is not available to order yet, as we are currently running several clinical evidence studies. If you are interested to find out more details please send your question via Contact us and we will reply within 2 working days.


Q: What is the difference between this test and genetic tests?

A: IMMray™ PanCan-d shows the actual status of the pancreatic cancer in the body, whereas genetic tests just evaluate the risks for the disease.